Academician help! Chinese experts' consensus on clinical application of Ginkgo biloba extract injection

On December 6, the 2019 Beijing Forum on cerebrovascular diseases and the annual meeting of Beijing Association for the prevention and control of cerebrovascular diseases were held in Beijing In the opening part of the conference, the consensus of Chinese experts on the clinical application of Ginkgo biloba extract injection was solemnly launched Open the app to read the latest report Left six: Wang Yongjun, President of Tiantan Hospital; left five: Zhao Xingquan, Professor of Tiantan Hospital; right three: Qi Xiaokun, Professor of the sixth medical center of the PLA; left one: Song Haiqing, Professor of Xuanwu Hospital at 9:00 a.m, Academician Zhao Jizong, neurosurgeon expert of Tiantan Hospital and President of Beijing Cerebrovascular Disease Prevention Association Wang Zhi Professor Jiang, Ms Gao Xiaolan, former Secretary of the Party committee of Tiantan Hospital, Professor Zhao Xingquan, Secretary General of Beijing cerebrovascular disease prevention association, director of Neurology center of Tiantan Hospital, Deputy Secretary General of China stroke society, vice president of Beijing cerebrovascular disease prevention association, director of Neurology Department of the sixth Medical Center of the PLA, and chairman of Neurology Professional Committee of Medical Science Committee of the PLA Professor Kun, Mr Yu Fei, executive director of Beijing cerebrovascular disease prevention association and chairman assistant of yuekang Pharmaceutical Group, jointly launched the "handprint platform", which is hand-to-hand connected and United, and shocked the launch of "China expert consensus on clinical application of Ginkgo biloba extract injection" Third from the right: academician Zhao Jizong, neurosurgery expert of Tiantan Hospital; first from the left: President Wang Zhijiang, Beijing cerebrovascular disease prevention association; second from the left: Professor Zhao Xingquan, Tiantan Hospital; third from the left: Ms Gao Xiaolan, former party secretary of Tiantan Hospital; second from the right: Professor Qi Xiaokun, the sixth medical center of the PLA; Right one: Mr Yu Fei, assistant to the president of yuekang Pharmaceutical Group, Ginkgo biloba extract injection has a wide range of clinical applications This consensus is compiled around key issues in clinical applications, and is more close to clinical application combining evidence-based medicine literature evidence and clinical application experience of multi-disciplinary experts It is helpful for clinicians to fully understand and use Ginkgo biloba extract injection from the aspects of origin of imported raw materials, quality level, composition mechanism, safety test, basic clinical research, etc Experts have indicated that in the future, we will work with many other doctors to further study, regularly update and improve the consensus, and guide clinical medication The Chinese expert consensus on the clinical application of Ginkgo biloba extract injection was written by more than 30 experts in various fields in China organized by Beijing cerebrovascular disease prevention and Control Association After one year of repeated discussion, it was published in the Chinese Journal of geriatric medicine in November 2019 and in the 2019 Beijing Forum on cerebrovascular disease and the annual meeting of Beijing cerebrovascular disease prevention and Control Association on December 6, 2019 Ginkgo biloba extract injection is recommended by consensus for the treatment of ischemic stroke, dementia, deafness, tinnitus, vertigo, coronary heart disease, retinopathy and arteriosclerosis obliterans Yuekang pharmaceutical, adhering to the strategy of "pharmaceutical 100%, imported into France in 2012 Indena company produces listed yuekangtong? Ginkgo biloba extract injection as the raw material of Ginkgo biloba extract, optimizes the production process, and has more strict quality control indicators such as heavy metals and agricultural residues It has dual patents for EU raw materials and Chinese preparations, and is the only Ginkgo biloba extract injection that has obtained the approval of National Drug Administration for domestic chemicals, and entered the country in 2019 The catalogue of Western medicine for medical insurance is necessary for clinical treatment.